肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验正式开始

2019-01-29 MedSci MedSci原创

PembrolizumabEDP1503直肠癌
关注

Evelo是一家开发单克隆微生物的生物技术公司，近日宣布EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验的第一例患者已正式入组。EDP​​1503是一种口服递送的单克隆微生物候选药物，预期用于治疗癌症。

Evelo是一家开发单克隆微生物的生物技术公司，近日宣布EDP1503联合pembrolizumab治疗多种肿瘤的I/II临床试验的第一例患者已正式入组。EDP​​1503是一种口服递送的单克隆微生物候选药物，预期用于治疗癌症。

这项开放标签的临床试验将评估EDP1503联合pembrolizumab在多达120名患者中的安全性、耐受性、免疫应答标记和总体反应率。这些患者可以分为三组：微卫星稳定结的直肠癌、三阴性乳腺癌、其他肿瘤的患者，且这些患者在先前的PD-1 / L1抑制剂治疗后复发。患者每天接受EDP1503单药治疗两周，然后每日EDP1503与pembrolizumab联合治疗。Evelo预计将在2020年上半年报告试验的初始临床数据。

肿瘤内科主任医学博士Humphrey Gardner说：“EDP1503的这项临床试验将使我们能够探索EDP1503和pembrolizumab之间潜在的协同作用，并提供治疗多种癌症类型的潜力”。在临床前研究中，口服递送的EDP1503显示多种临床验证的系统免疫途径的激活，其与检查点抑制剂互补并且可能与检查点抑制剂协同。


原始出处：

http://www.firstwordpharma.com/node/1615774?tsid=4#axzz5bnF206kJ

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Jan 09 12:50:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912076, encodeId=179b19120e6dc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Mar 13 22:50:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727867, encodeId=241d1e27867cc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 16 02:50:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272533, encodeId=adf512e25333b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jan 30 23:50:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359564, encodeId=14e9359564c9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Jan 30 10:54:54 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2020-01-09 chendoc242

    #Pembro#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Jan 09 12:50:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912076, encodeId=179b19120e6dc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Mar 13 22:50:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727867, encodeId=241d1e27867cc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 16 02:50:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272533, encodeId=adf512e25333b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jan 30 23:50:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359564, encodeId=14e9359564c9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Jan 30 10:54:54 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-03-13 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Jan 09 12:50:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912076, encodeId=179b19120e6dc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Mar 13 22:50:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727867, encodeId=241d1e27867cc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 16 02:50:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272533, encodeId=adf512e25333b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jan 30 23:50:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359564, encodeId=14e9359564c9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Jan 30 10:54:54 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-07-16 feather89

    #PE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Jan 09 12:50:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912076, encodeId=179b19120e6dc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Mar 13 22:50:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727867, encodeId=241d1e27867cc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 16 02:50:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272533, encodeId=adf512e25333b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jan 30 23:50:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359564, encodeId=14e9359564c9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Jan 30 10:54:54 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 hxj0117

    #Pembrolizumab#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1786992, encodeId=90ed1e8699248, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14026, encryptionId=38601402654, topicName=Pembro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Thu Jan 09 12:50:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912076, encodeId=179b19120e6dc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Mar 13 22:50:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727867, encodeId=241d1e27867cc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Jul 16 02:50:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1272533, encodeId=adf512e25333b, content=<a href='/topic/show?id=4323140286a' target=_blank style='color:#2F92EE;'>#Pembrolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14028, encryptionId=4323140286a, topicName=Pembrolizumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jan 30 23:50:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359564, encodeId=14e9359564c9, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Jan 30 10:54:54 CST 2019, time=2019-01-30, status=1, ipAttribution=)]
    2019-01-30 一天没事干

    很好的学习机会

    0

相关资讯

JCO：Epacadostat 联合 Pembrolizumab治疗晚期实体瘤

肿瘤可通过上调IDO1酶来逃避免疫监视。Epacadostat是一种有效且高度选择性的IDO1酶抑制剂。Pembrolizumab是一种PD1抑制剂。ECHO-202 / KEYNOTE-037试验评估了epacadostat联合pembrolizumab治疗晚期实体瘤患者的效果。I期试验主要报告最大耐受剂量，安全性，耐受性，初步抗肿瘤活性和药代动力学结果。

JCO：Pembrolizumab治疗具有脑转移的黑色素瘤：II期临床

Pembrolizumab在黑色素瘤脑转移瘤中具有活性，具有可接受的毒性和持久的反应。

Generex生物制药公司与NSABP基金会签署临床试验协议：开展AE37联合Pem​​brolizumab治疗三阴性乳腺癌的临床试验

Generex生物制药公司已与NSABP基金会签署临床试验协议（CTA），以推进Pem​​brolizumab与AE37肽疫苗联合的II期临床试验，用于治疗转移性三阴性乳腺癌，计划于2019年的一季度招募患者。

JCO：Pembrolizumab新辅助治疗肌层浸润性膀胱癌

JCO近期发表了一篇文章，研究pembrolizumab作为肌层浸润性膀胱癌（MIBC）患者接受根治性膀胱切除术（RC）之前的新辅助治疗的有效性。

CLIN CANCER RES：基线肿瘤大小是接受Pembrolizumab治疗的黑色素瘤患者的独立预后因素

CLINCANCER RES近期发表了一篇文章，通过KEYNOTE-001队列的数据研究基线肿瘤大小（BTS）与接受pembrolizumab治疗的晚期黑色素瘤患者预后之间的关系。

Lancet：Pembrolizumab用于晚期头颈癌效果显著

Pembrolizumab治疗晚期头颈癌效果显著